Syndecan-1 a Surrogate Marker for IBD (syndecan1)

Clalit Health Services

Status: Completed

Conditions: Inflammatory Bowel Diseases

Treatments: Procedure: blood sample; Procedure: Blood sample - venous blood 10 ml.

Study type: Observational

Funder types: Other

Identifiers

NCT01430039

03.09.11.01

31.08.11 (Registry Identifier)

Details and patient eligibility

About

Syndecan-1 is a protein on the surface intestinal cells. previous studies proved low levels of mucosal syndecan-1 levels on the surface of intestinal cells is patients with acute and chronic inflammation due to inflammatory bowel disease.

this protein might shed from cell surface to the serum. The investigators wish to prove that elevated serum levels of syndecan-1 may be predictive of disease presence, extent and severity, that buy taking a simple blood sample from patients diagnosed with inflammatory bowel disease and comparing to normal subjects and to other markers.

Full description

One of the main hypothesis for the etiology of Inflammatory bowel disease (IBD) is an inappropriate and ongoing activation of the mucosal immune system in response to the presence of normal luminal flora. This aberrant response is most likely facilitated by defects in both the barrier function and the mucosal immune system of the intestinal epithelium. Syndecans are a class proteoglycans that take part in both cell adhesion and growth factor binding. Of the four known syndecan core proteins, syndecan-1 (CD138) and one of the best studied of this group and is also the relevant to the this study as it is expressed on the basolateral surface of columnar epithelial cells of the colon. Syndecan-1 functions as an integral membrane protein that participates in cell proliferation, cell migration and cell matrix interactions in the GI tract. Evidence for a reduction of syndecan-1 expression in the regenerating epithelium that overlies inflamed tissue was reported in both acute and chronic inflammation. This protein that is lost from the inflamed mucosal membrane might shed to the serum. Elevated serum levels of syndecan-1 may be predictive of disease presence and extent.

Enrollment: 42 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• informed consent
• no other concurrent inflammatory disease
• formal diagnosis of inflammatory bowel disease i.e Crohn's disease, Ulcerative colitis

Exclusion criteria

• pregnancy
• fever at time of sample taking

Trial design

42 participants in 2 patient groups

Crohn's, ulcerative colitis

Description:

Patients with diagnosed with Crohn's disease or ulcerative colitis who agreed to participate in the study and singed informed consent and answered a Crohn's disease activity index questioner for Crohn's disease or the ulcerative colitis activity index questioner for ulcerative colitis.

Treatment:

Procedure: Blood sample - venous blood 10 ml.

No disease

Description:

Healthy subjects with no known inflammatory disease. For basal serum levels of syndecan 1

Treatment:

Procedure: blood sample